Decision: Favourable
Study Title:
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
NREC Code:
23-NREC-CT-011
Decision:
Favourable
Meeting Date:
08/02/2023
Study Type:
CT application
Principal Investigator:
Dr Declan O'Rourke
PI Institution:
Children's Health Ireland at Temple Street
Sponsor:
Dyne Therapeutics, Inc.